Search

Your search keyword '"MOREL H"' showing total 10 results
Start Over Author "MOREL H" Journal annals of oncology
10 results on '"MOREL H"'

1. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study

Author

Bourgeois, H., Grudé, F., Solal-Céligny, P., Dupuis, O., Voog, E., Ganem, G., Denis, F., Zinger, M., Juhel-Voog, L., Lafond, C., Maillart, P., Capitain, O., Delva, R., Soulié, P., Abadie-Lacourtoisie, S., Guérin-Meyer, V., Morin-Meschin, M.E., Commer, J.M., Gangler, A., d’Aillières, B., Zannetti, A., Bourbouloux, E., Berton-Rigault, D., Lebouvier-Sadot, S., Kaassis, M., Baudon, J., Lam, Y.H., Bizieux, A., Marcq, M., Edeline, J., Le Du, F., Lefeuvre, C., Deguiral, P., Delecroix, V., Blot, E., Egreteau, J., Goudier, M.J., Lamy, R., Ferec, M., Artignan, X., Corbinais, S., Morel, H., Hardy-Bessard, A.C., Alleaume, C., Naudeix, E., Cojocarasu, O., Metges, J.P., Riché, C., Gamelin, E., Déniel-Lagadec, D., Marhuenda, F., Ingrand, P., and Douillard, J.Y.

Published
2017
Full Text
View/download PDF

2. 1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy

Author

Bronstein, A., primary, Gervais, R., additional, Monnet, I., additional, Ricordel, C., additional, Bigay-Game, L., additional, Geier, M., additional, Decroisette, C., additional, Daniel, C., additional, Guisier, F., additional, Swalduz, A., additional, Toffart, A.C., additional, Doubre, H., additional, Peloni, J.M., additional, Arpin, D., additional, Morel, H., additional, Veillon, R., additional, Clarisse, B., additional, Chouaid, C., additional, Greillier, L., additional, and Bylicki, O., additional

Published
2022
Full Text
View/download PDF

3. 1016P GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies

Author

Bylicki, O., primary, Gervais, R., additional, Monnet, I., additional, Ricordel, C., additional, Bigay-Game, L., additional, Geier, M., additional, Decroisette, C., additional, Daniel, C., additional, Guisier, F., additional, Swalduz, A., additional, Toffart, A.C., additional, Doubre, H., additional, Peloni, J.M., additional, Arpin, D., additional, Morel, H., additional, Veillon, R., additional, Clarisse, B., additional, Martins-Lavinas, P-H., additional, Greillier, L., additional, and Chouaid, C., additional

Published
2022
Full Text
View/download PDF

5. 1202P ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib

Author

Debieuvre, D., primary, Locher, C., additional, Morel, H., additional, Baranzelli, A., additional, Falchero, L., additional, Romand, P., additional, Roa, M., additional, Delclaux, B., additional, Bizieux-Thaminy, A., additional, Bugnet, A-S., additional, Grelier, J., additional, Dayen, C., additional, Decroisette, C., additional, Martinez, S., additional, Goutorbe, F., additional, Moreau, L., additional, Cloarec, N., additional, Molinier, O., additional, Le Treut, J., additional, and Duval, Y., additional

Published
2021
Full Text
View/download PDF

7. 1326P Liver metastasis but not bone metastasis impact overall survival of advanced non-small cell lung cancer (NSCLC) treated by nivolumab (GFPC 04-2016)

Author

Decroisette, C., primary, Guisier, F., additional, Bylicki, O., additional, Lamy, R., additional, Geier, M., additional, Morel, H., additional, Bizieux, A., additional, Vieillot, S., additional, Bernardi, M., additional, Janicot, H., additional, Boissiere, L., additional, Justeau, G., additional, Gervais, R., additional, Doubre, H., additional, Le Garff, G., additional, Vergnenegre, A., additional, and Chouaid, C., additional

Published
2020
Full Text
View/download PDF

8. 1273P Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial

Author

Barlesi, F., primary, Karimi, M., additional, Tomasini, P., additional, Daniel, C., additional, Raimbourg, J., additional, Quoix, A-E., additional, Flandin, A-C. Madroszyk, additional, Mazieres, J., additional, Molinier, O., additional, Audigier-Valette, C., additional, Moro-Sibilot, D., additional, Morel, H., additional, Souquet, P-J., additional, Bieche, I., additional, Tran-Dien, A., additional, Jacquet, A., additional, Adam, J., additional, Soria, J-C., additional, and Besse, B., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results